IBIO · iBio, Inc.

The Board of iBio, Inc. appointed Dr. Elizabeth Stoner, an experienced biotech leader with prior roles at Merck, Semma Therapeutics, and Rhythm Pharmaceuticals, as a Class II director effective May 7, 2026, following the Nominating and Corporate Governance Committee's recommendation. This appointment fills the vacancy created by Evert Schimmelpennink's immediate resignation from the Board and Compensation Committee, which was not due to any disagreements. Dr. Stoner, also serving on the Compensation Committee, brings extensive clinical development expertise across more than 40 countries and current board roles at LIB Therapeutics and Antiva Bioscience. Her compensation aligns with non-employee director standards, including cash fees and equity incentives vesting over 36 months. The press release highlights her value in advancing iBio's clinical-stage pipeline, including IBIO-610 and IBIO-600, as the company nears its first human trial.